Sezary syndrome
MONDO:0017844Sezary syndrome (SS) is an aggressive form of cutaneous T-cell lymphoma characterized by a triad of erythroderma, lymphadenopathy and circulating atypical lymphocytes (Sezary cells).
Also known as: CTCL / Sezary syndrome, SC)zary syndrome, Sezary disease, Sezary lymphoma, Sezary syndrome, Sezary's disease, Sheehan Syndrome, Sézary lymphoma
3118 clinical trials for this condition and its sub-types, 45 tagged with Sezary syndrome itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New hope for rare skin cancer: targeted antibody tested in china
Disease control CompletedThis study tests a drug called mogamulizumab in 23 Chinese adults with mycosis fungoides or Sézary syndrome, two types of skin lymphoma that have not responded to previous treatments. The drug is given as an IV infusion and aims to shrink or eliminate cancer in the skin, lymph no…
Phase 4 • Sponsor: Kyowa Kirin China Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New drug cocktail aims to tackle rare blood cancer
Disease control CompletedThis phase 2 trial tested whether combining two drugs, romidepsin and lenalidomide, is safe and effective for people with peripheral T-cell lymphoma (PTCL) who haven't had treatment yet. PTCL is a rare blood cancer with no standard therapy, and current options like CHOP chemother…
Phase 2 • Sponsor: Northwestern University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Real-World study confirms Mogamulizumab's effectiveness against rare skin cancer
Disease control CompletedThis study looked at 100 adults with cutaneous T-cell lymphoma (a rare type of skin cancer) who had already tried at least one other treatment. Researchers wanted to see how well the drug mogamulizumab works in everyday medical practice, not just in controlled trials. They measur…
Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New antibody shows promise for rare blood cancers
Disease control CompletedThis phase 2 trial tested a drug called lacutamab (IPH4102) in 170 people with advanced T-cell lymphoma, including Sezary syndrome and mycosis fungoides. The drug is an antibody that targets a protein on cancer cells. It was given alone or with chemotherapy to see if it could shr…
Phase 2 • Sponsor: Innate Pharma • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New Two-Step transplant shows promise for blood cancer patients
Disease control CompletedThis study tested a two-step stem cell transplant for people with blood cancers like leukemia and lymphoma. First, patients received low-dose chemotherapy and radiation to prepare their bodies. Then, they got donor stem cells followed by drugs to prevent the donor cells from atta…
Phase 2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Can a daily mood diary reveal how steroids affect emotions?
Knowledge-focused CompletedThis study follows patients with cutaneous T-cell lymphoma or chronic cluster headache who are receiving corticosteroid treatment as part of their regular care. Participants fill out a short daily questionnaire on their phone for about 40 days, starting a few days before treatmen…
Sponsor: Leiden University Medical Center • Aim: Knowledge-focused
Last updated Aug 29, 2026 00:00 UTC
-
Real-World study tracks Poteligeo's impact on rare skin cancer symptoms
Knowledge-focused CompletedThis completed observational study followed 73 adults with mycosis fungoides or Sézary syndrome who were starting treatment with Poteligeo. Researchers tracked changes in symptoms like itching, skin pain, and fatigue, as well as quality of life for patients and their caregivers. …
Sponsor: Kyowa Kirin Pharmaceutical Development Ltd • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC